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OBJECTIVE — In an underserved Latino area, we established a disease-management pro-
gram and proved its effectiveness. However, many patients still remained above target. This
study was designed to evaluate which factors are associated with reaching program goals.
RESEARCH DESIGN AND METHODS — This was a randomized, prospective, obser-
vational study in which patients enrolled in our program were followed for 2 years with out-
comes, measures, and questionnaires assessed at baseline and at 6, 12, and 24 months.
RESULTS — Overall, A1C fell by 1%. Adherence to medication was the strongest predictor of
reaching the target A1C of 8%; baseline A1C was also predictive. Knowledge scores increased in
those who reached target, but the measures of self-efﬁcacy and empowerment did not change for
either group.
CONCLUSIONS — Diabetes management is effective in a lower-income Latino population.
However, adherence was suboptimal even when medications were provided on-site for free.
Further research into barriers associated with medication adherence is needed.
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I
ntheU.S.,Latinoindividualshaveahigh
prevalenceofdiabetesandareoftenpoor
and uninsured (1). Research needs to be
done to develop cost-effective, ethnically
appropriate diabetes programs for these
vulnerable individuals. We implemented a
diabetes-management program in a com-
prehensive health center serving low-
income,LatinopatientsineastLosAngeles.
A previous study indicated that our pro-
gram improves short-term outcomes but
thattheimprovementisoftennotsustained
(2). This study was conducted to identify
the correlates of success in our program.
RESEARCH DESIGN AND
METHODS— Thisstudywasa2-year
one-centerrandomizedcomparativetrial.
Consenting patients entering our pro-
gram were randomized to either an epi-
sodic model of care or a continuous
model of care. Each patient completed an
Institutional Review Board–approved in-
formed consent form. All subjects under-
went the same ﬁrst 6 months of care in
accordance with our protocols. After 6
months, those in the episodic group were
to be discharged and returned annually
for an evaluation. Those in the continu-
ous model were seen at least every 3
months for the duration of 2 years. Pa-
tients were randomized and frequency
matched based on age, diabetes duration,
sex, BMI, and A1C.
Routine diabetes clinical and labora-
tory measurements and questionnaires
(Diabetes Knowledge Test [3], the Sum-
mary of Diabetes Self-Care Activities
questionnaire [4], Diabetes Empower-
ment Scale [5], and the Problem Areas in
Diabetes questionnaire [6]) were com-
pleted at baseline and at 6, 12, and 24
months. Adherence to prescribed drugs
was measured as a medication possession
ratio (MPR), which represents the pro-
portion of days on which the patient had
the medication available (7).
The design of our program has previ-
ously been described (2). Most patients
have no health insurance and live below
the federal poverty level. Care managers
(nurses and nurse practitioners) provide
care following protocols and are super-
vised by a diabetologist. The program at-
tempts global risk reduction in a culturally
appropriate context. Our A1C target is
8%, with recommendations for reduc-
ing the A1C further in primary care. Ini-
tially, we followed patients indeﬁnitely,
but resources mandated shortening the
programs duration to 6 months, with a
possibleextensionbasedonthejudgment
of the care manager.
Statistical analysis
Data are presented as means  SEM.
Changes in each variable from baseline at
each follow-up time were compared be-
tween the two groups using a two-way
Student’s t test. For all behavioral re-
sponse measures, the scores of responses
foreachquestionnairewerecomparedbe-
tweenthetwogroupsatbaselineandeach
visit using Wilcoxon’s rank-sum test.
Data were analyzed using GraphPad In-
stat 3, version 3.0b.
We conducted a multivariate logistic
regression analysis on patients treated
withmetformin(themostfrequentlyused
medication) to determine the factors as-
sociated with a patient’s probability of
achieving an A1C 8% at the last fol-
low-up evaluation. The key regressor, ad-
herence to metformin, was deﬁned as the
fraction of time metformin was available
tothepatient.Othercovariatesincludeda
set of demographics (sex, age, education,
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conditions (duration of diabetes at base-
line, baseline A1C, and drug treatment at
baseline). The model was analyzed using
Stata Statistical Software, version 10.1.
RESULTS— Of 211 eligible patients,
162 were enrolled, with 79 in the control
groupand83intheepisodicgroup.Inthe
ﬁrst year, 129 patients (79.7%) com-
pletedtheprogram,and100(61.7%)had
data available during the second year.
Baseline mean A1C values were 7.9 
1.8%(control)and7.71.6%(episodic)
and fell by 1% at 6 and 12 months in
both groups. However, the total number
of visits was the same in the control and
episodic groups, erasing the separation
between the models. No relationship was
found between the number of visits and
change in A1C.
Subsequent analyses compared those
who reached the A1C target of 8% with
those who did not. Ninety-six subjects
(62%)achievedthetargetof8%,and59
(38%) were above the target. Patients in
the group with 8% A1C showed signif-
icant improvements on the Summary of
Diabetes Self-Care Activities question-
naire in diet and foot care as well as
improvements on the Diabetes Knowl-
edge Test. These variables did not im-
prove in the 8% A1C group. No
signiﬁcant changes were seen on the Di-
abetes Empowerment Scale or the Prob-
lem Areas in Diabetes questionnaire in
either group.
Regression results are presented in
Table 1. Factors that are statistically sig-
niﬁcant include adherence to metformin
and A1C at baseline with odds ratios of
19.31 (95% CI 2.16–172.60; P  0.01)
and 0.51 (0.36–0.73; P  0.00), respec-
tively. The results suggest that the proba-
bility of reaching the 8% A1C target
increases with higher adherence to met-
formin and lower baseline A1C levels.
Basedonbothpharmacydataandpa-
tient self-report, rates of self-monitoring
of blood glucose did not differ between
groups (30 strips obtained and report-
edly used per month). No differences
wereseeninvisitstowalk-inclinicsorthe
emergency department or in rates of in-
patient hospitalization.
CONCLUSIONS — This study showed
a 1% sustained reduction in A1C through
diabetesmanagement.Adherenceisasta-
tisticallysigniﬁcant(P0.01)androbust
predictor for the 8% target at follow-up.
Other studies have found a similar relation-
ship between medication adherence and
outcomesinindividualstreatedfordiabetes
(8,9). Unlike most diabetic patients in most
settings, however, our patients are able to
obtain their prescriptions for free in the
same building where they are seen for their
diabetes care.
Limitations to our study include the
failure of the initial episodic model to be
implemented, the use of medication at-
tainment as a measure for medication ad-
herence (less accurate than actual pill
counts but more accurate than patient
self-report) (10), and a high dropout rate
in the second year.
The surveys used did not capture
the psychosocial stressors of our pa-
tients. The need for study of barriers to
self-management has been discussed by
others(11).Additionally,manyofourpa-
tientsexperiencefoodinsecurity(12)and
lack access to the recommended healthy
foods (13). These considerations make
more traditional questions about lifestyle
and stress more difﬁcult to interpret.
In conclusion, medication adherence
was a strong predictor of maintaining an
A1C level below target. Incorporating
new approaches to enhance adherence
(14,15) might help improve outcomes.
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